KalVista Pharmaceuticals Inc (NASDAQ: KALV) is 53.96% higher on its value in year-to-date trading and has touched a low of $7.30 and a high of $15.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The KALV stock was last observed hovering at around $12.96 in the last trading session, with the day’s gains setting it 0.08%.
Currently trading at $13.04, the stock is 2.32% and 5.45% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.8 million and changing 0.62% at the moment leaves the stock 19.17% off its SMA200. KALV registered 5.59% gain for a year compared to 6-month gain of 43.45%.
The stock witnessed a 11.84% loss in the last 1 month and extending the period to 3 months gives it a 4.40%, and is -11.65% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.59% over the week and 3.44% over the month.
KalVista Pharmaceuticals Inc (KALV) has around 150 employees, a market worth around $648.29M and $0.00M in sales. Distance from 52-week low is 78.63% and -15.87% from its 52-week high. The company has generated returns on investments over the last 12 months (-70.24%).
The EPS is expected to shrink by -3.28% this year.
KalVista Pharmaceuticals Inc (KALV) Top Institutional Holders
The shares outstanding are 49.49M, and float is at 38.49M with Short Float at 16.16%.
The top institutional shareholder in the company is VR ADVISER, LLC with over 6.25 million shares valued at $73.62 million. The investor’s holdings represent 13.5179% of the KALV Shares outstanding. As of 2024-06-30, the second largest holder is TANG CAPITAL MANAGEMENT LLC with 4.22 million shares valued at $49.7 million to account for 9.1252 of the shares outstanding. The other top investors are SUVRETTA CAPITAL MANAGEMENT, LLC which holds 4.19 million shares representing 9.0671% and valued at over $49.38 million, while FRAZIER LIFE SCIENCES MANAGEMENT, L.P. holds 7.9767 of the shares totaling 3.69 million with a market value of $43.44 million.
KalVista Pharmaceuticals Inc (KALV) Insider Activity
The most recent transaction is an insider sale by Palleiko Benjamin L, the company’s CHIEF EXECUTIVE OFFICER. SEC filings show that Palleiko Benjamin L sold 7,169 shares of the company’s common stock on Jun 09 ’25 at a price of $14.50 per share for a total of $0.1 million. Following the sale, the insider now owns 0.32 million shares.
KalVista Pharmaceuticals Inc disclosed in a document filed with the SEC on May 23 ’25 that Audhya Paul K. (CHIEF MEDICAL OFFICER) sold a total of 2,146 shares of the company’s common stock. The trade occurred on May 23 ’25 and was made at $11.31 per share for $24272.0. Following the transaction, the insider now directly holds 0.11 million shares of the KALV stock.
Still, SEC filings show that on May 23 ’25, Yea Christopher (CHIEF DEVELOPMENT OFFICER) disposed off 1,926 shares at an average price of $11.31 for $21782.0. The insider now directly holds 98,189 shares of KalVista Pharmaceuticals Inc (KALV).
